^
Association details:
| Biomarker: | TMB-H + PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5464 / 14 - Predictive biomarkers for PD-1 and PD-L1 checkpoint inhibitor response in NSCLC: An analysis of clinical trial and real-world data Add to My Itinerary
Published date:
03/15/2023
Excerpt:
The combination of high TMB and PD-L1 expression was the strongest predictor of durable response (OR = 0.04; CI = 0.00, 0.20; P< .001)….This study supports the predictive utility of PD-L1 expression and TMB for NSCLC patients receiving CPI therapy and further elucidates their utility in patient sub-populations.
Source:
Title:
490 - A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC
Published date:
03/10/2021
Excerpt:
TMB cut-off for objective response rate (ORR) in two independent cohorts (DFCI and MSKCC) of pts with NSCLC treated with ICI....A TMB ≥90th percentile correlated with longer PFS/OS among NSCLCs with PD-L1 levels ≥50% and 1-49%, and longer PFS among those with PD-L1 <1% (Table).
Source:
Title:
Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer
Published date:
02/03/2021
Excerpt:
Eighteen genes were significantly associated with longer progression-free survival (PFS) or better response. The number of mutated genes within 18 favorable genes were defined as TMS18. TMS18 (HR = 0.307, P < 0.001) had smaller hazard ratio and P value than TMB (HR = 0.455, P = 0.004) and PD-L1 expression (HR = 0.403, P = 0.005) in survival analysis. Moreover, TMS18 had significantly higher AUC than TMB and TMS18 combined with PD-L1 improved the accuracy.
DOI:
10.1007/s00262-021-02868-w
Source:
Title:
1037P - Tumour mutational burden and HLA diversity by TruSight oncology 500 (TSO500) next generation sequencing panel and clinical outcome in non-small cell lung cancer
Published date:
09/14/2020
Excerpt:
NSCLC patients with high TMB by TSO500, show higher RR to immunotherapy. HLA diversity score alone could not predict response, however combined high TMB and HLA diversity score show higher RR and DCR. Combined TMB, HLA diversity and PD-L1 can identify NSCLC patients likely to respond to or unlikely to benefit from IO. Hence TMB and HLA diversity score should be considered part of comprehensive genomic profiling.
